Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) announced that its LockeT suture retention device will be featured in live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference.
The event runs February 11–13, 2026 at the Hyatt Regency La Jolla at Aventine in San Diego, and inclusion in live cases highlights LockeT's role in workflow efficiency and patient recovery after venous catheter access, according to the company.
Positive
- None.
Negative
- None.
News Market Reaction – VTAK
In the Feb 5 session, VTAK declined 4.81%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | LockeT adoption update | Positive | +1.6% | Reported new hospital evaluations, approvals, and strongest January revenue for LockeT. |
| Jan 22 | German market entry | Positive | +10.4% | First LockeT purchase order in Germany, entering a large EP devices market. |
| Jan 20 | VIVO expansion | Positive | -1.9% | VIVO purchase order in Slovenia expanding commercial footprint to 15 countries. |
| Dec 18 | Irish LockeT contract | Positive | +0.9% | First LockeT purchase order and multi‑year commitment at major Irish EP center. |
| Dec 03 | Hungary VIVO tender | Positive | +13.3% | Multi‑year VIVO tender win in Hungary, extending reach in Central/Eastern Europe. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has focused on international expansion and adoption of LockeT and VIVO, with most positive updates followed by positive price reactions, but at least one instance of divergence.
Over the past few months, Catheter Precision highlighted commercialization of LockeT and VIVO across Europe and new markets. Key milestones included a first LockeT purchase order in Germany on Jan 22, 2026, expansion of VIVO into Slovenia bringing its footprint to 15 countries, and an Irish multi‑year LockeT commitment announced on Dec 18, 2025. Earlier, a multi‑year VIVO tender win in Hungary signaled Central and Eastern European growth. Today’s conference-focused news continues the theme of clinical adoption and visibility for LockeT.
Key Terms
cardiac electrophysiology medical
suture retention device medical
structural heart disease medical
venous catheter access medical
interventional cardiologists medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference. The event, hosted by Scripps Health, will take place from February 11–13, 2026, at the Hyatt Regency La Jolla at Aventine in San Diego.
The Scripps Structural Heart course is a premier educational forum featuring state-of-the-art, live case-based reviews of structural heart disease interventions and cardiovascular imaging. Leading interventional cardiologists from across the country are presenting at the conference and the inclusion of LockeT in live cases underscores the device's growing role in streamlining workflow efficiency and enhancing patient recovery after venous catheter access.
“We are honored to have LockeT showcased at such a prestigious clinical gathering,” said David Jenkins, CEO of Catheter Precision. “As we enter 2026 with strong momentum and expansion into major medical centers like Scripps in Southern California, these live cases provide a vital platform for physicians to witness firsthand the operational and economic advantages of our suture retention technology.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
